Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia

Mesenteric Ischemia Clinical Trial

Official title:

Predictive Factors of Intestinal Infraction in Patients With Acute Mesenteric Ischemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02645240
• Other study ID #: mansoura30
• Status: Completed
• Phase: Phase 4
• First received: December 29, 2015
• Last updated: August 28, 2017
• Start date: October 2015
• Est. completion date: August 2017

Study information

• Verified date: August 2017
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to identify several factors that can accurately predict the incident of intestinal infraction in patients with mesenteric vascular occlusion or ischemia.

Description:

The study aims to identify several clinical, laboratory, and radiologic factors that can accurately predict the occurrence of intestinal infraction in patients with mesenteric vascular occlusion or ischemia in order to prevent unnecessary surgical intervention in patients with just intestinal ischemia and to hasten intervention in patients with actual intestinal gangrene.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: August 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients with acute mesenteric Ischemia

Exclusion Criteria:

• Patients with other causes of acute abdomen other than mesenteric Ischemia

Related Conditions & MeSH terms

• Ischemia
• Mesenteric Ischemia

Intervention

Drug:
• Heparin injection
Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours

Locations

Country	Name	City	State
Egypt	Mansoura university hospital	Mansoura	Dakahlia

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical improvement	Number of patients with resolved abdominal symptoms and incidence of patients developing shock	48 hours